CXCR4 and neoplasm: The use of CXCR4 antagonists, such as plerixafor (AMD3100), balixafortide, and POL5551, is one such approach that, in tandem with standard chemotherapeutics (e.g., doxorubicin or paclitaxel), produced a synergistic effect, resensitizing TNBC cells to apoptosis, and reduced tumour burden [19].